FDA Fast-Tracks Psychedelic-Based Mental Health Treatments as Aging America Faces Rising Long-Term Care Risk

Transient functional improvements in advanced Alzheimer's disease following high-dose psilocybin: a case report

This case report describes an 80-year-old Japanese-American woman with advanced Alzheimer's disease (10-year history, 5 years of severe hypo

The debate about whether the NHS should use magic mushrooms to treat depression

Severe Alzheimer's patient shows improved cognition and speech after psilocybin dose

A case report describes a woman with severe Alzheimer's disease who, after receiving a large dose of psilocybin, began initiating conversati

Severe Alzheimer's patient shows improved cognition and speech after psilocybin dose

A case report describes a woman with severe Alzheimer's disease who, after receiving a large dose of psilocybin, began initiating conversati

Psychedelic Nation? Psilocybin Treatments Offer New Hope for People Prozac Hasn’t Helped

Psilocybin Delays Cellular Aging and Extends Lifespan in Preclinical Study

Psilocybin, the active compound in psychedelic mushrooms, significantly delayed cellular aging and extended lifespan in a preclinical study

Synthetic Psilocybin Shows Strong Results in Treatment-Resistant Depression Trials

Compass Pathways, a British biotech company, announced strong results from two late-stage trials showing that a synthetic form of psilocybin